Myomo Inc
$ 0.85
7.18%
17 Apr - close price
- Market Cap 30,578,300 USD
- Current Price $ 0.85
- High / Low $ 0.86 / 0.78
- Stock P/E N/A
- Book Value 0.30
- EPS -0.37
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.86 %
- 52 Week High 4.99
- 52 Week Low 0.60
About
Myomo, Inc., a portable medical robotics company, designs, develops and produces myoelectric braces for people with neuromuscular disorders in the United States. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$4.32
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-16 | 2025-11-10 | 2025-08-11 | 2025-05-06 | 2025-03-05 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-03-07 | 2023-11-07 | 2023-08-09 | 2023-05-10 |
| Reported EPS | -0.0852 | -0.09 | -0.12 | -0.08 | -0.01 | -0.03 | -0.03 | -0.1 | -0.07 | -0.06 | -0.04 | -0.11 |
| Estimated EPS | -0.084 | -0.11 | -0.1 | -0.1 | -0.0233 | -0.04 | -0.07 | -0.1 | -0.06 | -0.09 | -0.03 | -0.13 |
| Surprise | -0.0012 | 0.02 | -0.02 | 0.02 | 0.0133 | 0.01 | 0.04 | 0 | -0.01 | 0.03 | -0.01 | 0.02 |
| Surprise Percentage | -1.4286% | 18.1818% | -20% | 20% | 57.0815% | 25% | 57.1429% | 0% | -16.6667% | 33.3333% | -33.3333% | 15.3846% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYO
2026-04-16 20:39:53
MYOMO, Inc. Director William J. Febbo was granted 45,000 restricted stock units (RSUs) as equity compensation under the company's 2018 Stock Option and Incentive Plan. This grant, valued at $0.00 per share, vests entirely on the first anniversary of the grant date. Following this transaction, Febbo's direct beneficial ownership of MYOMO shares totals 45,000.
2026-04-16 20:39:53
Myomo (NYSE: MYO) director William J. Febbo has filed an initial Form 3, which is a required statement for new insiders. This administrative filing confirms his insider status but indicates no stock transactions or holdings at this time. The filing was made on April 16, 2026, and officially reports his appointment as a director.
2026-04-16 20:39:52
Myomo, Inc. (NYSE: MYO) announced the appointment of William Febbo to its Board of Directors, effective April 14, 2026. Febbo brings over 30 years of experience in healthcare, financial services, and technology, including significant growth leadership at OptimizeRx, where he expanded revenue from $5 million to $92 million. His compensation package includes an initial grant of 45,000 restricted stock units, an annual cash retainer of $60,000, and $85,000 in additional annual RSUs.
2026-04-16 19:39:52
Myomo, Inc. has announced the appointment of William "Will" Febbo to its Board of Directors, effective April 14, 2026. Febbo brings over 30 years of experience in healthcare, finance, and technology, with a strong background in scaling healthcare solutions and capital markets initiatives. Myomo expects his expertise to be instrumental in their strategy for direct-to-patient healthcare solutions and increasing investor awareness.
2026-04-16 19:39:52
Myomo, Inc., a wearable medical robotics company, has appointed William “Will” Febbo to its Board of Directors, effective April 14, 2026. Febbo brings over 30 years of experience in healthcare, financial services, and technology-driven businesses, and is expected to contribute significantly to the company's growth, particularly in scaling innovative direct-to-patient healthcare solutions and enhancing Myomo's capital markets awareness. He previously served as CEO of OptimizeRx Corporation, where he led a significant transformation and revenue growth.
2026-04-14 23:40:30
Myomo's CEO, Paul R. Gudonis, acquired 16,666 Restricted Stock Units (RSUs) by exchanging three months of his salary, as detailed in an amended Form 4 filing. This transaction is part of a company program allowing employees to convert 10% of their salary into RSUs valued at 115% of the exchanged salary. The RSUs are set to vest entirely on July 9, 2026, and after this grant, Gudonis directly holds 1,277,316 shares of the company's common stock.
